Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Xenon Pharmaceuticals (NASDAQ:XENE) had its target price lifted by stock analysts at Wells Fargo & Company from $48.00 to $49.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target would indicate a potential upside of 13.35% from the company’s previous close.

A number of other equities analysts have also recently weighed in on XENE. Needham & Company LLC reissued a “buy” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Royal Bank Of Canada raised their target price on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Wolfe Research assumed coverage on shares of Xenon Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Friday, January 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $55.50.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $43.23 on Friday. The stock has a market capitalization of $3.34 billion, a P/E ratio of -9.92 and a beta of 0.96. Xenon Pharmaceuticals has a 1 year low of $26.74 and a 1 year high of $46.99. The business’s fifty day moving average is $42.49 and its two-hundred day moving average is $41.04.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period last year, the company earned ($0.84) earnings per share. On average, research analysts forecast that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Insider Activity

In related news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $266,580. This trade represents a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 65,205 shares of company stock valued at $2,919,762 over the last ninety days. 4.07% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Holocene Advisors LP acquired a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter valued at $56,637,000. Wellington Management Group LLP increased its stake in shares of Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after acquiring an additional 1,435,096 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Xenon Pharmaceuticals by 1,294.2% during the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock worth $30,369,000 after acquiring an additional 900,746 shares in the last quarter. Braidwell LP boosted its position in Xenon Pharmaceuticals by 33.0% during the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after purchasing an additional 895,154 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Xenon Pharmaceuticals by 1,968.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock valued at $38,650,000 after purchasing an additional 820,608 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Two analyst upgrades lift sentiment — Needham raised its price target to $58 with a Buy rating and Wells Fargo nudged its target to $49 with an Overweight rating, implying meaningful upside from current levels, which supports longer-term investor interest. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Company update highlights near-term clinical catalysts and strong pro forma cash runway — Xenon reiterated a Phase 3 topline readout for azetukalner (X-TOLE2) expected in early March and reported pro forma cash (~$716M) that management says extends runway into H2 2027, reducing near-term financing risk and keeping the pipeline-funded. Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst/press commentary stresses pipeline focus despite higher R&D — Coverage (e.g., Zacks) notes a wider Q4 loss driven by a 47% jump in R&D spend but underscores ongoing late‑stage azetukalner trials and early-stage pain programs; useful context but not an immediate stock mover beyond the earnings reaction. Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
• Negative Sentiment: Refreshed $400M at-the-market (ATM) equity program — Xenon filed to refresh an ATM capacity, which increases the potential for share issuance. While it provides financing optionality, investors often view ATM refreshes as a near-term dilution risk that can pressure the stock. Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program
• Negative Sentiment: Q4 EPS missed estimates — Xenon reported ($1.31) EPS vs. consensus ($1.20), a larger loss year-over-year; the miss likely contributed to intra-day selling despite the pipeline updates. Xenon Reports Q4 and Full Year 2025 Financial Results (Press Release PDF)

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.